Northern Trust Corp Purchases Shares of 63,199 Arcus Biosciences Inc (RCUS)

Northern Trust Corp purchased a new position in Arcus Biosciences Inc (NYSE:RCUS) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 63,199 shares of the company’s stock, valued at approximately $774,000. Northern Trust Corp owned about 0.14% of Arcus Biosciences at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Hillhouse Capital Management Ltd. lifted its position in shares of Arcus Biosciences by 80.5% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 767,128 shares of the company’s stock worth $9,390,000 after purchasing an additional 342,128 shares during the last quarter. BlackRock Inc. lifted its position in shares of Arcus Biosciences by 1,606.3% during the 2nd quarter. BlackRock Inc. now owns 335,270 shares of the company’s stock worth $4,104,000 after purchasing an additional 315,621 shares during the last quarter. Vident Investment Advisory LLC acquired a new position in shares of Arcus Biosciences during the 2nd quarter worth about $1,911,000. Baker BROS. Advisors LP acquired a new position in shares of Arcus Biosciences during the 2nd quarter worth about $1,488,000. Finally, Platinum Investment Management Ltd. increased its stake in Arcus Biosciences by 428.4% during the second quarter. Platinum Investment Management Ltd. now owns 52,841 shares of the company’s stock valued at $647,000 after acquiring an additional 42,841 shares during the period. 39.11% of the stock is owned by institutional investors.

In other news, President Juan C. Jaen purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, November 13th. The shares were purchased at an average cost of $11.80 per share, for a total transaction of $118,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several brokerages recently issued reports on RCUS. Zacks Investment Research lowered Arcus Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, September 19th. Wedbush began coverage on Arcus Biosciences in a research note on Tuesday, October 9th. They set an “outperform” rating and a $22.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $18.60.

Shares of RCUS opened at $11.92 on Friday. Arcus Biosciences Inc has a 12-month low of $9.50 and a 12-month high of $22.10.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.13. The firm had revenue of $4.29 million for the quarter, compared to the consensus estimate of $1.40 million. As a group, equities research analysts predict that Arcus Biosciences Inc will post -2.04 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/12/07/northern-trust-corp-purchases-shares-of-63199-arcus-biosciences-inc-rcus.html.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences Inc (NYSE:RCUS).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply